Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19

Autor: Fadel, Raef, Morrison, Austin R, Vahia, Amit, Smith, Zachary R, Chaudhry, Zohra, Bhargava, Pallavi, Miller, Joseph, Kenney, Rachel M, Alangaden, George, Ramesh, Mayur S, Nauriyal, Varidhi, Lakshmikanth, Jayanth, Abdul Hamed, Asif, Nadeem, Owais, Griebe, Kristin, Johnson, Joseph M, Bradley, Patrick, Uduman, Junior, Hegab, Sara, Swiderek, Jennifer, Godfrey, Amanda, Jennings, Jeffrey, Gardner-Gray, Jayna, Ackerman, Adam, Lezotte, Jonathan, Ruhala, Joseph, Samuel, Linoj, Tibbetts, Robert J, Brar, Indira, McKinnon, John, Suleyman, Geehan, Yared, Nicholas, Herc, Erica, Williams, Jonathan, Lanfranco, Odaliz Abreu, Chen, Anne, Zervos, Marcus, Scher, Eric

Publikováno v: Clinical Infectious Diseases
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Background There is no proven antiviral or immunomodulatory therapy for coronavirus disease 2019 (COVID-19). The disease progression associated with the proinflammatory host response prompted us to examine the role of early corticosteroid therapy in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be19a62c21e6ca88593abe4703f9c4b6